Vancouver’s Abdera Therapeutics, a biopharmaceutical company that utilizes its advanced antibody engineering platform to design and develop precision radiopharmaceuticals for cancer, has announced that it has raised $142 million in combined Series A and B financing. The Series A round was led by Versant Ventures and Amplitude Ventures, with participation from Northview Ventures, adMare BioInnovations, […]